A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

(2019) Alison Crawford et al.   Science Translational Medicine

CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies

(2018) Marina Bacac et al.   CLINICAL CANCER RESEARCH

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?

(2018) Paula Salmikangas et al.   PHARMACEUTICAL RESEARCH

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

F-Actin-Driven CD28-CD80 Localization in the Immune Synapse

(2018) Anastasios Siokis et al.   Cell Reports

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

(2017) Véronique Diéras et al.   LANCET ONCOLOGY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection

(2016) Eugene A Zhukovsky et al.   CURRENT OPINION IN IMMUNOLOGY

CD28 Costimulation: From Mechanism to Therapy

(2016) Jonathan H. Esensten et al.   IMMUNITY

Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity

(2016) Andrew D. Tustian et al.   mAbs

Toxicity and management in CAR T-cell therapy

(2016) Challice L Bonifant et al.   Molecular Therapy-Oncolytics

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS

(2015) Miguel F. Sanmamed et al.   SEMINARS IN ONCOLOGY

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

(2015) Eric J. Smith et al.   Scientific Reports

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies

(2014) Xiaoyu Yang et al.   CURRENT OPINION IN BIOTECHNOLOGY

What Counts in the Immunological Synapse?

(2014) Michael L. Dustin   MOLECULAR CELL

Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

(2014) L. E. Macdonald et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

(2014) A. J. Murphy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crosstalk between Human IgG Isotypes and Murine Effector Cells

(2012) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

After TGN1412: Recent developments in cytokine release assays

(2012) R. Stebbings et al.   Journal of Immunotoxicology

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells

(2010) D Eastwood et al.   BRITISH JOURNAL OF PHARMACOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE